The FINANCIAL -- Novartis announced today new data from the Phase III 2309 study showing patients with relapsing-remitting multiple sclerosis treated with Gilenya had a statistically significant 48% reduction in annualized relapse rates at 24 months compared to placebo.

The FINANCIAL -- Tis’ the season for sneezing, coughing and fevers. As the temperature drops and cold and flu season gets under way, parental anxiety is expected to rise.

The FINANCIAL -- Results from THALASSA, the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade in patients with non-transfusion-dependent thalassemia, show that Exjade can significantly reduce iron overload.

The FINANCIAL -- Bayer HealthCare has submitted an application for marketing authorization in the European Union and in the U.S. for a new low dose levonorgestrel releasing intrauterine system for long-term contraception of up to three years.